Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Assets (2019 - 2025)

Historic Assets for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $998.2 million.

  • BridgeBio Pharma's Assets rose 5011.8% to $998.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $998.2 million, marking a year-over-year increase of 5011.8%. This contributed to the annual value of $919.3 million for FY2024, which is 6825.98% up from last year.
  • BridgeBio Pharma's Assets amounted to $998.2 million in Q3 2025, which was up 5011.8% from $1.1 billion recorded in Q2 2025.
  • BridgeBio Pharma's Assets' 5-year high stood at $1.1 billion during Q1 2021, with a 5-year trough of $503.7 million in Q2 2023.
  • Its 5-year average for Assets is $816.6 million, with a median of $813.1 million in 2022.
  • As far as peak fluctuations go, BridgeBio Pharma's Assets tumbled by 4158.64% in 2023, and later skyrocketed by 6825.98% in 2024.
  • BridgeBio Pharma's Assets (Quarter) stood at $1.0 billion in 2021, then plummeted by 38.48% to $623.0 million in 2022, then dropped by 12.3% to $546.4 million in 2023, then soared by 68.26% to $919.3 million in 2024, then grew by 8.58% to $998.2 million in 2025.
  • Its Assets was $998.2 million in Q3 2025, compared to $1.1 billion in Q2 2025 and $881.6 million in Q1 2025.